Neutral · 50/100Sep 17, 11:28 AM EDT
RBC Initiates GRAIL at Sector Perform with $84 Target Ahead of FDA Panel on Galleri
GRAL
RBC Capital Markets initiated coverage on GRAIL with a Sector Perform rating and an $84 price target. The call comes ahead of an FDA Advisory Committee meeting to discuss U.S. authorization for GRAIL's Galleri multi-cancer early detection test. The AdCom outco…
- ▹FDA AdCom pending for Galleri creates regulatory uncertainty; no accelerated path or surrogate endpoint confirmed.
- ▹Multi-cancer early detection platform has potential but remains pre-commercial with no reimbursement support yet.